Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide-siRNA Nanocomplexes.

  title={Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide-siRNA Nanocomplexes.},
  author={Justin H Lo and Ester J. Kwon and Angela Q. Zhang and Preeti Singhal and Sangeeta N. Bhatia},
  journal={Bioconjugate chemistry},
  volume={27 10},
Nanoparticulate systems have shown great promise in overcoming the considerable trafficking barriers associated with systemic nucleic acid delivery, which must be addressed to unlock the full potential of technologies such as RNAi and gene editing in vivo. In addition to mediating the cytoplasmic delivery of nucleic cargo and shielding it from nuclease degradation and immunostimulation, nucleic-acid-containing nanomaterials delivered intravenously must also be stable in the bloodstream after… 

Figures and Tables from this paper

PEGylation rate influences peptide‐based nanoparticles mediated siRNA delivery in vitro and in vivo

iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer

iRGD TPNs hold promise in treating pancreatic ductal adenocarcinoma by not only overcoming physical barriers to therapy, but by leveraging the stroma to achieve knockdown of the gold-standard genetic target.

Peptide Spiders: Peptide-Polymer Conjugates to Traffic Nucleic Acids.

This work linked two trafficking peptides to the PEG backbone using either nonreducible or reducible chemistries and investigated the ability of these materials to carry silencing RNAs into mammalian cells, and investigates peptide-polymer linkages.

Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics

E engineered nanoparticles carrying a CpG DNA ligand of TLR9 can suppress tumor growth in several animal models of various cancers, resulting in an abscopal effect on distant tumors, and improving responsiveness to anti-CTLA4 treatment with combinatorial effects after intratumoral administration.

Co-Delivery of Repurposing Itraconazole and VEGF siRNA by Composite Nanoparticulate System for Collaborative Anti-Angiogenesis and Anti-Tumor Efficacy against Breast Cancer

In vitro and in vivo experiments showed that the nanoparticles could induce the silencing of VEGF-related expressions as well as anti-angiogenesis efficacy, and the co-loaded ITZ-VEGF siRNA NPs could inhibit tumor growth effectively with low toxicity and side effects.

A Review of the Current State of Nanomedicines for Targeting and Treatment of Cancers: Achievements and Future Challenges

This review attempts to address the issue by using a weight of evidence approach to the different strategies for use of nanomedicines in combating cancer, as well as highlighting a number of areas that the field of nanosized carrier systems is clearly lagging behind in, as compared to conventional drug discovery and development.

Non-viral delivery of CRISPR/Cas9 complex using CRISPR-GPS nanocomplexes.

A simple and modular tandem peptide-based nanocomplex system with cell-targeting capacity that efficiently combines guide RNA with Cas9 protein, and facilitates internalization of sgRNA/Cas9 ribonucleoprotein complexes to yield robust genome editing across multiple cell lines is reported.

Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer

The benefits of anti-miR-21, miR-217 mimic or siKRAS loaded into the tumor-penetrating nanoparticles (TPN) that had been shown to potently target the largely impenetrable PDAC tumors are found, and an enhanced anti-tumoral response upon dual treatments in KRAS-mutated PDAC models are found.

Tissue distribution following 28 day repeated oral administration of aluminum‐based nanoparticles with different properties and the in vitro toxicity

It is suggested that the physicochemical properties of NPs should be examined in detail before the release into the market to prevent unexpected adverse health effects.

Personalized RNA Medicine for Pancreatic Cancer

This general approach appears suitable for co-clinical validation of personalized RNA medicine and paves the way to prospectively identify patients with eligible miRNA profiles for personalized RNA-based therapy.



Multifunctional polymeric micelles for delivery of drugs and siRNA

The purpose of this review is to highlight recent advances in the development of multifunctional polymeric micelles specifically for delivery of drugs and siRNA, as well as discuss the potential and suitability of multi-functional polymeric mouselles, including lipid-based micella, as promising vehicles for both siRNA and drugs.

The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice.

Improvements to siRNA stability and pharmacokinetics are highlighted, key determinants for development of clinically relevant RNAi therapeutics.

A non-covalent peptide-based carrier for in vivo delivery of DNA mimics

Pep-3 is described, a short amphipathic peptide that combines a tryptophan/phenylalanine domain with a lysine/arginine-rich hydrophilic motif that forms stable nano-size complexes with peptide-nucleic acid analogues and promotes their efficient delivery into a wide variety of cell lines, including primary and suspension lines, without any associated cytotoxicity.

PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles.

In comparing polyplexes and their PEGylated variants, significant differences in particle morphology, cellular uptake, and resultant expression suggest that in vitro studies should be conducted with particles prepared for physiological conditions if the results are to be relevant to in vivo performance.

Identification and Characterization of Receptor-Specific Peptides for siRNA Delivery

A library of tandem tumor-targeting and cell-penetrating peptides that condense siRNA into stable nanocomplexes for cell type-specific siRNA delivery and identifies a subset of the library that are taken up by cells via endocytosis, trigger endosomal escape and unpacking of the carrier, and deliver siRNA to the cytosol in a receptor-specific fashion.

Polymer brush-stabilized polyplex for a siRNA carrier with long circulatory half-life.

  • Ayumi SatoS. Choi A. Maruyama
  • Biology, Chemistry
    Journal of controlled release : official journal of the Controlled Release Society
  • 2007

Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo.

These collective findings validate the functional significance of tuning the balance of cationic and hydrophobic content of polyplex NPs utilized for systemic siRNA delivery in vivo.

Cooperative nanomaterial system to sensitize, target, and treat tumors

A cooperative nanosystem consisting of two discrete nanomaterials that binds to the stress-related protein, p32, which is found to be upregulated on the surface of tumor-associated cells upon thermal treatment, and displays significant reductions in tumor volume compared with individual nanoparticles or untargeted cooperative system.

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

A new class of lipid-like delivery molecules, termed lipidoids, are described, that facilitate high levels of specific silencing of endogenous gene transcripts when formulated with either double-stranded small interfering RNA (siRNA) or single-Stranded antisense 2′-O-methyl (2′-OMe) oligoribonucleotides targeting microRNA (miRNA).